Theranostics- the use of radiolabelled compounds for therapy and diagnosis 

April 12, 09:00 – 16:30


Lecture Hall IX, University Main Building, Uppsala
Biskopsgatan 3
Uppsala, 75105 Sweden

Theranostics- the use of radiolabelled compounds for therapy and diagnosis 

April 12, 2024 @ 09:00 16:30 CEST

Theranostics. Image Courtesy of Marika Nestor.

Welcome to a symposium arranged by the Drug Discovery and Development platform together with the Department of Immunology, Genetics and Pathology at Uppsala University and the Department of Oncology and Pathology at Karolinska Institutet. You can expect to learn and discuss different topics reaching from selecting a target for therapy, the research process to develop a candidate drug to the regulatory framework for theranostics.

Theranostics is a term used to describe when radioactive drugs are used as diagnostic and therapeutic pairs. Receptors that are overexpressed in the diseased tissue, e.g. tumors, are used to guide the drug to the target. The radiation can then either be used to for imaging or for therapy depending on the radionuclide used. Developing a theranostic agent could be a feasible way to reach the clinic and SciLifeLab is well suited to catalyze this process. We have gathered renowned speakers to discuss different aspects of the process from bench to bedside. We envision to inspire researcher with clinically relevant ideas to consider this relatively new technique as a feasible approach to reach the clinic. We also hope to gather researchers that are already in the field as well as infrastructure personnel.


9.00-9.20 Welcome and Introduction to SciLifeLab

9.20-10.10 “Theranostics and Radiomolecular Precision Oncology: Navigating the Past and Charting the Future of Nuclear Medicine.” (Professor Richard Baum, Curanosticum, Wiesbaden-Frankfurt) 

10.10-10.40 Coffee and posters 

10.40-11.20 Why We Need New Targets for Radiopharmaceutical Therapy – and How to Find Them (Assistant Professor Kasper Karlsson, KI)  

11.20-12 ” Translating innovation: Advancing the cancer radiopharmaceutical 177Lu-AKIR001 to clinical trials” (Professor Marika Nestor, UU) 

12-13.00 Lunch and posters 

13.00-13.40 Dosimetry for Biologists: From Mouse Model Extrapolations to Considerations for Implementation of Radiopharmaceuticals in Clinical Practice (Professor Peter Bernhardt, GU)

13.40-14.20 Theranostics from a Regulatory Perspective (Dr Anna Sundlöf, Clinical Assessor, Swedish Medical Product Agency)

14.20-15 Development of a Theranostic Product Pair for Patients with HER2 Expressing Disease: An Industrial Perspective (Professor Fredrik Frejd, CSO, Affibody AB) 

15.00-15.30 Coffee and posters

15.30-16.00 Theranostic Specific Infrastructures for Your Research/Project: From Bench to Bedside – Associate professor Thuy Tran and Associate Professor Renske Altena, KI

16.00-16.30 Panel Discussion

16.30 Concluding Remarks

Organizing committee

Marika Nestor, Uppsala University
Thuy Tran, Karolinska Institutet
Jonas Rehn, Elekta
Ulrika Yngve, SciLifeLab Drug Discovery and Development Platform

Last updated: 2024-04-03

Content Responsible: Isolde Palombo(